These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
285 related items for PubMed ID: 9387950
1. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N. Eur Respir J; 1997 Oct; 10(10):2260-3. PubMed ID: 9387950 [Abstract] [Full Text] [Related]
2. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Eur Respir J; 1998 Feb; 11(2):428-33. PubMed ID: 9551749 [Abstract] [Full Text] [Related]
3. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG, RAPID Trial Study Group. Lancet; 2015 Jul 25; 386(9991):360-8. PubMed ID: 26026936 [Abstract] [Full Text] [Related]
4. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med; 1998 Jul 25; 158(1):49-59. PubMed ID: 9655706 [Abstract] [Full Text] [Related]
5. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Piitulainen E, Eriksson S. Eur Respir J; 1999 Feb 25; 13(2):247-51. PubMed ID: 10065663 [Abstract] [Full Text] [Related]
11. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Wencker M, Fuhrmann B, Banik N, Konietzko N, Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen. Chest; 2001 Mar 25; 119(3):737-44. PubMed ID: 11243951 [Abstract] [Full Text] [Related]
13. Exacerbations and duration of smoking abstinence are associated with the annual loss of FEV1 in individuals with PiZZ alpha-1-antitrypsin deficiency. Fähndrich S, Bernhard N, Lepper PM, Vogelmeier C, Seibert M, Wagenpfeil S, Bals R. Respir Med; 2017 Aug 25; 129():8-15. PubMed ID: 28732839 [Abstract] [Full Text] [Related]